MX2025009965A - Compuestos sustituidos de pirazolopirimidina y su uso medico - Google Patents
Compuestos sustituidos de pirazolopirimidina y su uso medicoInfo
- Publication number
- MX2025009965A MX2025009965A MX2025009965A MX2025009965A MX2025009965A MX 2025009965 A MX2025009965 A MX 2025009965A MX 2025009965 A MX2025009965 A MX 2025009965A MX 2025009965 A MX2025009965 A MX 2025009965A MX 2025009965 A MX2025009965 A MX 2025009965A
- Authority
- MX
- Mexico
- Prior art keywords
- medical use
- substituted pyrazolopyrimidine
- pyrazolopyrimidine compounds
- formula
- substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023027432 | 2023-02-24 | ||
| PCT/JP2024/006433 WO2024177127A1 (ja) | 2023-02-24 | 2024-02-22 | 置換ピラゾロピリミジン化合物及びその医薬用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2025009965A true MX2025009965A (es) | 2025-09-02 |
Family
ID=92501386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025009965A MX2025009965A (es) | 2023-02-24 | 2025-08-22 | Compuestos sustituidos de pirazolopirimidina y su uso medico |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4671247A1 (enExample) |
| JP (2) | JP7737490B2 (enExample) |
| KR (1) | KR20250151389A (enExample) |
| CN (1) | CN120752239A (enExample) |
| AR (1) | AR131919A1 (enExample) |
| AU (1) | AU2024226032A1 (enExample) |
| CO (1) | CO2025011311A2 (enExample) |
| IL (1) | IL322520A (enExample) |
| MX (1) | MX2025009965A (enExample) |
| TW (1) | TW202448887A (enExample) |
| WO (1) | WO2024177127A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025140708A1 (zh) * | 2023-12-31 | 2025-07-03 | 杭州百新生物医药科技有限公司 | 吡唑并嘧啶类化合物及其医药用途 |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3064498T3 (pl) * | 2013-10-30 | 2020-03-31 | Shanghai Hengrui Pharmaceutical Co. Ltd. | Pirazolopirymidon lub pochodne pirolotriazonu, sposób ich otrzymywania i ich zastosowania farmaceutyczne |
| WO2017205766A1 (en) * | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
| ES2930151T3 (es) * | 2019-01-14 | 2022-12-07 | Innate Tumor Immunity Inc | Moduladores heterocíclicos de NLRP3, para su uso en el tratamiento del cáncer |
| KR102865929B1 (ko) * | 2019-01-14 | 2025-09-29 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Nlrp3 조정제 |
| WO2021132577A1 (ja) * | 2019-12-27 | 2021-07-01 | 日本たばこ産業株式会社 | アシルスルファミド化合物及びその医薬用途 |
| US20240382488A1 (en) * | 2021-03-29 | 2024-11-21 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| JP2024513227A (ja) * | 2021-04-05 | 2024-03-22 | ハリア・セラピューティクス・インコーポレイテッド | Ｎｅｋ７阻害剤 |
| US20240287079A1 (en) * | 2021-08-31 | 2024-08-29 | Japan Tobacco Inc. | 6-aminopyrazolopyrimidine compound and pharmaceutical use thereof |
| WO2024048519A1 (ja) * | 2022-08-29 | 2024-03-07 | 日本たばこ産業株式会社 | ピラゾロピリミジン化合物及びその医薬用途 |
| AU2024255473A1 (en) * | 2023-04-14 | 2025-10-16 | Takeda Pharmaceutical Company Limited | Pyrazolopyrimidine derivatives as inhibitors of nlrp3 |
-
2024
- 2024-02-22 AR ARP240100407A patent/AR131919A1/es unknown
- 2024-02-22 JP JP2024025063A patent/JP7737490B2/ja active Active
- 2024-02-22 CN CN202480014319.1A patent/CN120752239A/zh active Pending
- 2024-02-22 IL IL322520A patent/IL322520A/en unknown
- 2024-02-22 EP EP24760425.9A patent/EP4671247A1/en active Pending
- 2024-02-22 KR KR1020257027024A patent/KR20250151389A/ko active Pending
- 2024-02-22 TW TW113106397A patent/TW202448887A/zh unknown
- 2024-02-22 AU AU2024226032A patent/AU2024226032A1/en active Pending
- 2024-02-22 WO PCT/JP2024/006433 patent/WO2024177127A1/ja not_active Ceased
-
2025
- 2025-08-21 CO CONC2025/0011311A patent/CO2025011311A2/es unknown
- 2025-08-22 MX MX2025009965A patent/MX2025009965A/es unknown
- 2025-08-29 JP JP2025143871A patent/JP2025176085A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2024226032A1 (en) | 2025-09-11 |
| IL322520A (en) | 2025-10-01 |
| CO2025011311A2 (es) | 2025-09-08 |
| CN120752239A (zh) | 2025-10-03 |
| WO2024177127A1 (ja) | 2024-08-29 |
| TW202448887A (zh) | 2024-12-16 |
| JP7737490B2 (ja) | 2025-09-10 |
| AR131919A1 (es) | 2025-05-14 |
| KR20250151389A (ko) | 2025-10-21 |
| JP2024120882A (ja) | 2024-09-05 |
| EP4671247A1 (en) | 2025-12-31 |
| JP2025176085A (ja) | 2025-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025009965A (es) | Compuestos sustituidos de pirazolopirimidina y su uso medico | |
| ZA202501724B (en) | Pyrazolopyrimidine compound and pharmaceutical use thereof | |
| BR0308212A (pt) | Composto, composição farmacêutica, e, uso de um composto | |
| CY1110690T1 (el) | Ενωσεις 4-οξοκινολινης και χρησιμοποιηση αυτων ως αναστολεις της ενσωματασης του hiv | |
| BR112022022669A2 (pt) | Inibidores de nek7 quinase | |
| CO2024010774A2 (es) | Inhibidor del inflamosoma nlrp3 y uso del mismo | |
| BR0113496A (pt) | Composto ou um sal farmaceuticamente aceitável ou ester hidrolisável in vivo deste, uso destes, método para produzir um efeito inibidor do ciclo celular (anti-proliferação celular) em um animal de sangue quente, e, composição farmacêutica | |
| BRPI0413232B8 (pt) | composto tendo atividade inibitória contra transportador dependente de sódio, composição farmacêutica compreendendo o composto, uso do composto na preparação de um medicamento e processo para a preparação do composto | |
| BRPI0410563B8 (pt) | compostos de pirazol-quinazolina, seus processos de preparação e composições farmacêuticas | |
| BR0307575A (pt) | Derivados de sulfonila como inibidores de histona desacetilase | |
| MX2025001619A (es) | Inhibidor de pde4b y uso del mismo | |
| AR005053A1 (es) | Compuestos de difenilhexano, un procedimiento para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos, y procedmientos para la manufactura de medicamentos para inhibir la infeccion de hiv | |
| BR0312957A (pt) | Composto ou um sal farmaceuticamente aceitável deste, uso do mesmo, composição farmacêutica, e, método para produzir um efeito inibidor de 11betahsd1 em um animal de sangue quente, tal como o homem, em necessidade de tal tratamento | |
| BR0307607A (pt) | Derivados de carbonilamino como inibidores de histona desacetilase | |
| BR112023019435A2 (pt) | Inibidores de nek7 | |
| BR0315166A (pt) | Uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para produzir um efeito inibidor de 11betahsd1 em um animal de sangue quente, tal como o homem, que necessita de tratamento | |
| BRPI0409227C1 (pt) | composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i) | |
| AR119207A1 (es) | DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR | |
| BRPI0208811B8 (pt) | derivados de pirazol, seu uso e processo de preparação, bem como composição farmacêutica compreendendo os mesmos | |
| BR0317348A (pt) | EnantiÈmeros de derivados de ácido tiofeno hidroxâmico e seu uso como inibidores de hdac | |
| EA200400086A1 (ru) | Новые производные оксазолидинонов в качестве антибактериальных агентов | |
| DK0763017T3 (da) | N-(3-amino-2-hydroxybutyl)sulfonamidderivater som HIV-proteaseinhibitorer | |
| SE0300908D0 (sv) | Azaindole derivatives, preparations thereof, uses thereof and compositions containing them | |
| AR128066A1 (es) | Compuesto heterocíclico de pirimidina y método de preparación y uso médico de los mismos | |
| BR112023016986A2 (pt) | Compostos de aminopirimidina e métodos de seu uso |